Expand ACER Menu

About ACER

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna(R), is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ACER is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 87.7 M 8.77399E+07 1,991 1991 0.0% 2.9141E-06 813 813
UWM ProShares Ultra Russell2000 216.2 M 2.16193E+08 1,991 1991 0.0% 4.53436E-06 2,092 2092
VTWG Vanguard Russell 2000 Growth ETF 338.9 M 3.389E+08 1,171 1171 0.0% 1.67015E-05 5,843 5843
ITOT iShares Core S&P Total U.S. Stock Market ETF 26.3 B 2.63131E+10 3,660 3660 0.0% 0 1,730 1730
IWC iShares Microcap ETF 857.4 M 8.57401E+08 1,384 1384 0.01% 0.0001 70 K 70190
IWM iShares Russell 2000 ETF 45.2 B 4.51845E+10 1,981 1981 0.0% 0 491 K 491362
IWO iShares Russell 2000 Growth ETF 10.1 B 1.00609E+10 1,163 1163 0.0% 0 210 K 210062